GeneType MultiTest Panel Expanded Inclusion of New Diseases
Filed with ASX · · 2 pages · English
Melbourne, Australia, 27 March 2023:Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the initiation of phase 2 of the rollout plan for the geneType Multi-Test. The expanded panel now includes three new diseases taking the total number of individual risk assessments incl
Genetic Technologies Limited on 6ix
Earlier from Genetic Technologies
- Further Study Validates geneType Breast Cancer Risk Test
- Appendix 4D & Half-year Financial Report December 2022
- Receipt of R&D Tax Incentive Refund for geneType Multi Test
- Publication Highlights geneType Outperforms Current Models
- Business Update - February 2023
Later from Genetic Technologies
- Publication Validates geneType Prostate Cancer Risk Test
- Appendix 4C & Quarterly Activities Report - March 2023
- Publication Validates geneType for Melanoma Risk Assessment
- Appendix 4C and Quarterly Activities Report - June 2023
- Updated Investor Presentation - August 2023
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies